Inhibiting G9a/GLP improves engineered T-cell antitumor activity
The Insight Editing London team were delighted to see an early draft of this manuscript, before its submission to Nature Communications. Now accepted and available to read online, you can find out more about how researchers in Singapore and New York have aimed to improve the antitumor activity of engineered T cells.
Lam et al. found that short-term inhibition of G9a/GLP increases T-cell antitumor activity against hepatocellular carcinoma both in vitro and in a mouse model, by increasing granzyme expression and precipitating changes in pro-inflammatory gene expression.
Check out the full, open access article here: https://www.nature.com/articles/s41467-023-36160-5
This is a really interesting study with huge potential to change the efficacy of engineered T-cell therapy for many cancer patients. Congratulations to all those involved in this exciting work!